Table 1 Features of randomized clinical trials included in the meta-analysis
Trial | Study ID | Sex, No | Histology, No | Experimental arm (No.) | Control arm (No.) | Median follow-up time | PFS HR (95%CI) | OS HR (95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | Non-squamous | Squamous | Overall | Male | Female | Overall | Male | Female | |||||
NR | NCT01285609 | 635 | 114 | 0 | 749 | Ipilimumab + chemotherapy (388) | Placebo + chemotherapy (361) | 12.5 months vs 11.8 months | 0.87 (0.75–1.01) | NA | NA | 0.91 (0.77–1.07) | 0.85 (0.71–1.02) | 1.33 (0.84–2.11) |
Govindan et al. J Clin Oncol 2017 | ||||||||||||||
IMpower130 | NCT02367781 | 400 | 279 | 679 | 0 | Atezolizumab + chemotherapy (451) | Chemotherapy (228) | 18.5 months vs 19.2 months | 0.64 (0.54–0.77) | 0.67 (0.54–0.85) | 0.59 (0.45–0.78) | 0.79 (0.64–0.98) | 0.87 (0.66–1.15) | 0.66 (0.46–0.93) |
West et al. Lancet Oncol 2019 | ||||||||||||||
IMpower131 | NCT02367794 | 557 | 126 | 0 | 683 | Atezolizumab + chemotherapy (343) | Chemotherapy (340) | 26.8 months vs 24.8 months | NA | NA | NA | 0.88 (0.73–1.05) | 0.91 (0.75–1.12) | 0.68 (0.44–1.04) |
Jotte et al. J Thorac Oncol 2020 | ||||||||||||||
IMpower132 | NCT02657434 | 384 | 194 | 578 | 0 | Atezolizumab + chemotherapy (292) | Chemotherapy (286) | 28.4 months | 0.56 (0.47–0.67) | 0.61 (0.50–0.76) | 0.48 (0.35–0.66) | 0.86 (0.71–1.06) | 0.93 (0.73–1.18) | 0.76 (0.54–1.09) |
Nishio et al. J Thorac Oncol 2021 | ||||||||||||||
IMpower150 | NCT02366143 | 428 | 269 | 697 | 0 | Atezolizumab + bevacizumab + chemotherapy (359) | Bevacizumab + chemotherapy (338) | 39.8 months vs 40.0 months | 0.57 (0.48–0.67) | NA | NA | 0.80 (0.67–0.95) | 0.72 (0.58–0.90) | 0.92 (0.70–1.22) |
Socinski et al. J Thorac Oncol 2021 | ||||||||||||||
KEYNOTE-189 | NCT02578680 | 363 | 253 | 616 | 0 | Pembrolizumab + chemotherapy (410) | Placebo + chemotherapy (206) | 31.0 months | 0.49 (0.41–0.59) | 0.58 (0.46–0.74) | 0.39 (0.29–0.52) | 0.56 (0.46–0.69) | 0.74 (0.56–0.96) | 0.41 (0.30–0.56) |
Rodríguez-Abreu et al. Ann Oncol 2021 | ||||||||||||||
KEYNOTE-407 | NCT02775435 | 455 | 104 | 0 | 559 | Pembrolizumab + chemotherapy (278) | Placebo + chemotherapy (281) | 7.8 months | 0.56 (0.45–0.70) | 0.58 (0.46–0.73) | 0.49 (0.30–0.81) | 0.64 (0.49–0.85) | 0.69 (0.51–0.94) | 0.42 (0.22–0.81) |
Paz-Ares et al. N Engl J Med 2018 | ||||||||||||||
TASUKI-52 | NCT03117049 | 411 | 139 | 550 | 0 | Nivolumab + Bevacizumab + chemotherapy (275) | Placebo + Bevacizumab + chemotherapy (275) | 13.7 months | 0.57 (0.46–0.72) | 0.53 (0.41–0.69) | 0.72 (0.45–1.15) | 0.85 (0.63–1.14) | NA | NA |
Sugawara et al. Ann Oncol 2021 | ||||||||||||||
CheckMate 9LA | NCT03215706 | 504 | 215 | 495 | 224 | Nivolumab + ipilimumab + chemotherapy (361) | Chemotherapy (358) | 13.2 months | 0.68 (0.57–0.82) | 0.64 (0.52–0.79) | 0.82 (0.60–1.14) | 0.66 (0.55–0.80) | 0.66 (0.53–0.82) | 0.68 (0.47–1.00) |
Paz-Ares et al. Lancet Oncol 2021 | ||||||||||||||